Diagnostic research in immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis of research evolution, diagnostic focuses, and future priorities - Scorecard - MDSpire

Diagnostic research in immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis of research evolution, diagnostic focuses, and future priorities

  • By

  • Luwei Han

  • Wei Zhang

  • Qi Zhang

  • Wenhao Shen

  • Ping Yang

  • Bing Fang

  • Yuanxin Meng

  • Yi Liu

  • Ziyan Ren

  • Ruiyang Fei

  • Xinran Zhang

  • Jiaxing Li

  • Kaijin Lu

  • Gaohua Han

  • July 13, 2026

Share

Clinical Scorecard: A Bibliometric Study on the Evolution of Research, Diagnostic Approaches, and Future Directions in Immune Checkpoint Inhibitor-Associated Pneumonitis

At a Glance

CategoryDetail
ConditionImmune checkpoint inhibitor-related pneumonitis (CIP)
Key MechanismsInvolves immune checkpoint inhibitors targeting pathways like PD-1, PD-L1, and CTLA-4, leading to pulmonary toxicity.
Target PopulationPatients receiving cancer immunotherapy.
Care SettingOncology, immunology, thoracic medicine, and respiratory care.

Key Highlights

  • CIP research has significantly increased since 2015, with a notable rise in 2023.
  • Diagnostic assessment is complicated by overlapping symptoms with other conditions.
  • Chest CT findings in CIP are not specific and can resemble other pulmonary issues.
  • Key diagnostic themes include imaging features, bronchoalveolar lavage, and biomarkers.
  • Future research should focus on standardized diagnostic strategies linked to prognosis.

Guideline-Based Recommendations

Diagnosis

  • Consider patient history, symptom onset, CT findings, and tests for infection markers.

Management

  • Monitor for respiratory failure and consider interruption of anti-tumor therapy in severe cases.

Monitoring & Follow-up

  • Utilize multidisciplinary teams for comprehensive assessment and management.

Risks

  • CIP can lead to rapid deterioration and severe respiratory complications.

Patient & Prescribing Data

Patients undergoing treatment with immune checkpoint inhibitors.

Emphasis on differential diagnosis and risk stratification in managing CIP.

Clinical Best Practices

  • Incorporate imaging, BAL, and biomarkers in the diagnostic process.
  • Utilize a multidisciplinary approach for accurate diagnosis and management.

Related Resources & Content

    Original Source(s)

    Diagnostic research in immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis of research evolution, diagnostic focuses, and future priorities

    • by Luwei Han, Wei Zhang, Qi Zhang, Wenhao Shen, Ping Yang, Bing Fang, Yuanxin Meng, Yi Liu, Ziyan Ren, Ruiyang Fei, Xinran Zhang, Jiaxing Li, Kaijin Lu, Gaohua Han

    • July 13, 2026

    Related Content

    Tumor-associated macrophages and lineage plasticity in prostate cancer: from established myeloid programs to emerging spatial hypotheses

    Nutritional interventions in cancer management: a comprehensive scoping review

    Macrophage reprogramming through scavenger receptor-guided and cathepsin B-triggered nanodelivery: from intracellular mechanisms to translational applications